Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2020-001794-77-ES
EUCTR2020-001794-77-ES
Active, not recruiting
Phase 1

Phase II Clinical Trial to evaluate the efficacy of silibinin supplementation in the prevention of the progression of the respiratory failure in patients with onco-hematological diseases and infection by COVID-19 positive. - SilCOVID19

INSTITUT CATALÀ D'ONCOLOGIA GIRONA - HOSPITAL JOSEP TRUETA0 sites92 target enrollmentJuly 22, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCOVID19 respiratory failureTherapeutic area: Diseases [C] - Virus Diseases [C02]
DrugsLEGALON

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
COVID19 respiratory failure
Sponsor
INSTITUT CATALÀ D'ONCOLOGIA GIRONA - HOSPITAL JOSEP TRUETA
Enrollment
92
Status
Active, not recruiting
Last Updated
5 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 22, 2020
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
INSTITUT CATALÀ D'ONCOLOGIA GIRONA - HOSPITAL JOSEP TRUETA

Eligibility Criteria

Inclusion Criteria

  • •Personal history of active cancer.
  • •Confirmed COVID19 current infection
  • •Age \=18 years
  • •ECOG Performance Status \=2
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 62
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range 3

Exclusion Criteria

  • •Not possibility of receiving oral drugs
  • •Hemodinamic inestability
  • •Patients requiring non invasive ventilation or FIO2\> 50%
  • •Patient with a cancer survival prognosis \<3 months for its oncologic disease.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Study to evaluate the efficacy of FOLFIRI + aflibercept in patients with metastatic colorectal cancer previously treated with oxaliplatin with or without ACE polymorphismsMetastatic colorectal cancerMedDRA version: 19.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2016-001508-45-ESGrupo de Tratamiento de los Tumores Digestivos (TTD)100
Active, not recruiting
Not Applicable
Phase II clinical trial to evaluate the efficacy and safety in the use of pancreatic islets cells from cadaver donors for the treatment of Type-I Diabetes Mellitus in renal transplant patients.Type-I Diabetes Mellitus in renal trasplant patientsMedDRA version: 8.1Level: ptClassification code 10061835
EUCTR2005-004523-19-ESÁrea de Trasplante y Terapia Celular - Hospital Central de Asturias10
Active, not recruiting
Phase 1
Phase III clinical trial to evaluate the efficacy and safety of inhaled ethanol in the treatment of early-stage COVID-19.COVID-19Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2020-001760-29-ESSociedad Española de Farmacia Hospitalaria156
Active, not recruiting
Phase 1
Clinical Trial of allogeneic mesenchymal cells from umbilical cord tissue in patients with COVID-19.
EUCTR2020-001450-22-ESFundación de Investigación del Hospital Infantil Universitario Niño Jesús106
Active, not recruiting
Phase 1
Clinical trial to evaluate the effect of vitamin D on renal progression in patients with Chronic Kidney Disease and vitamin D deficiency
EUCTR2016-002913-23-ESFundación Hospital Alcorcón170